TFA Therapeutics (RAJAF) Invested Capital (2020 - 2025)

TFA Therapeutics has reported Invested Capital for 6 years, with the latest figure at $3.9 million in Q4 2025.

• On a quarterly basis, Invested Capital fell 0.64% year-over-year to $3.9 million in Q4 2025; TTM through Dec 2025 was $3.9 million, a 0.64% decrease from a year earlier, with the FY2025 full-year figure at $3.9 million, down 0.64% from the prior year.
• Invested Capital was $3.9 million for Q4 2025 at TFA Therapeutics, down from $4.0 million in the prior quarter.
• The five-year high for Invested Capital was $4.0 million in Q4 2024, with the low at -$210952.0 in Q4 2022.
• Average Invested Capital over 5 years is $2.3 million, with a median of $2.9 million recorded in 2021.
• The sharpest annual moves came in 2022 and 2023: Invested Capital tumbled 107.47% in 2022, then jumped 1467.55% in 2023.
• Over 5 years, Invested Capital stood at $2.8 million in 2021, then sank by 107.47% to -$210952.0 in 2022, then surged by 1467.55% to $2.9 million in 2023, then soared by 37.49% to $4.0 million in 2024, then retreated by 0.64% to $3.9 million in 2025.
• The last three Invested Capital figures came in at $3.9 million (Q4 2025), $4.0 million (Q4 2024), and $2.9 million (Q4 2023), per Business Quant data.